구조모아 (StructureMoa)항암 chemical structure spider web
방문Merck SharpDohme LLC
Immune Checkpoint Inhibitor(Merck Sharp & Dohme LLC)은 Gastric Cancer 표적 치료제로, Gastric Cancer; Second-line Treatment 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev. 전임상 단계입니다. 선택한 코호트에서 보고된 효능: ORR 59% (ClinicalTrials.gov NCT03729245). 차별점: novel strategies for combination therapy, is crucial for addressing the challenges posed by immunotherapy resistance and tumo.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Gastric Cancer
Gastric Cancer; Second-line Treatment
Recruiting
2026-09-02
Data Confidence · Low
Development Signal · Watch
Bispecific Antibodies in Solid Tumors: Mechanistic Insights, Clinical
humanized PD1 +/+ mice
novel strategies for combination therapy, is crucial for addressing the challenges posed by immunotherapy resistance and tumo
checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev
T cell exhaustion and recruitment
apoptosis resistance, migration, invasion, and epithelial-mesenchymal transition, as well as extracellular remodeling of the tumo
biomarker and its association with chemotherapy and immune checkpoint inhibitor resistance are critically eva
escape driven by multiple mechanisms
구조화 데이터
mouse tumor model
mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Merck SharpDohme LLC
Immune Checkpoint Inhibitor(Merck Sharp & Dohme LLC)은 Gastric Cancer 표적 치료제로, Gastric Cancer; Second-line Treatment 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev. 전임상 단계입니다. 선택한 코호트에서 보고된 효능: ORR 59% (ClinicalTrials.gov NCT03729245). 차별점: novel strategies for combination therapy, is crucial for addressing the challenges posed by immunotherapy resistance and tumo.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Gastric Cancer
Gastric Cancer; Second-line Treatment
Recruiting
2026-09-02
Data Confidence · Low
Development Signal · Watch
Bispecific Antibodies in Solid Tumors: Mechanistic Insights, Clinical
humanized PD1 +/+ mice
novel strategies for combination therapy, is crucial for addressing the challenges posed by immunotherapy resistance and tumo
checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev
T cell exhaustion and recruitment
apoptosis resistance, migration, invasion, and epithelial-mesenchymal transition, as well as extracellular remodeling of the tumo
biomarker and its association with chemotherapy and immune checkpoint inhibitor resistance are critically eva
escape driven by multiple mechanisms
구조화 데이터
mouse tumor model
mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.